Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...

Novo Nordisk accounts for 34% of the global ... qualities that it shares with the only two other global insulin players, Sanofi and Eli Lilly. However, we don't think Novo's cost advantages ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

The Senate Finance Committee advances the nomination of Robert F. Kennedy Jr. for HHS Secretary amid a party-line vote. Read ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

In 2024, Attorney General Ellison reached similar settlements with Eli Lilly and Sanofi, the other two defendants in the 2018 lawsuit. Monday’s settlement with Novo Nordisk means all Minnesotans ...